Mycosis fungoides (MF) is an extranodal cutaneous lymphoma that accounts for approximately 1% to 2% of all non-Hodgkin lymphomas. It is a rare disease, with approximately 2000 new cases diagnosed in the United States annually.
1,2 Mycosis fungoides disproportionately affects the elderly, with a median age of presentation at 57 years, and is twice as likely to occur in men as in women.
1,2 The most important prognostic factor for MF is stage at diagnosis. Early-stage disease occurs in the skin only with varying extent and severity, whereas advanced-stage disease can involve lymph nodes, blood, and visceral organs. Sézary syndrome (SS) is an advanced-stage leukemic form of MF involving the blood, lymph nodes, and erythroderma. Early-stage MF is often indolent, with a median survival of more than 20 years, whereas advanced disease can be rapidly life-threatening, with a median survival of 5 years.
3-5 Most patients are diagnosed with early-stage disease and live for many years, highlighting the importance of survivorship issues in this patient population.